SCHEMBL3340065 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	GAA	P10253	5/20	0.53

▸	ABL1	P00519	1/20	0.51

▸	KDM4E	B2RXH2	6/20	0.46

▸	ALDH1A1	P00352	5/20	0.45

▸	HSD17B10	Q99714	3/20	0.45

▸	MAPT	P10636	3/20	0.45

▸	GLA	P06280	2/20	0.45

▸	HPGD	P15428	2/20	0.45

▸	CASP1	P29466	1/20	0.45

▸	CASP7	P55210	1/20	0.45

▸	ATM	Q13315	1/20	0.45

▸	CFTR	P13569	3/20	0.44

▸	NQO2	P16083	6/20	0.43

▸	ALOX15	P16050	1/20	0.42

▸	TSHR	P16473	1/20	0.42

▸	NPSR1	Q6W5P4	1/20	0.41

▸	MEN1	O00255	1/20	0.40

▸	LMNA	P02545	1/20	0.40

▸	KMT2A	Q03164	1/20	0.40

▸	SMN1; SMN2	Q16637	1/20	0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL31546995	1.00	GAA (0.53)	GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL5595287	0.93	GAA (0.53)	GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL2395330	0.86	GAA (0.61)	GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL9793695	0.85	GAA (0.59)	GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL31508216	0.84	GAA (0.54)	GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL1786192	0.84	GAA (0.54)	GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL30697733	0.84	GAA (0.67)	GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL1787222	0.84	GAA (0.67)	GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL2897626	0.84	GAA (0.62)	GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL3651947	0.83	GAA (0.53)	GAAABL1KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-12441735-B2	Nitrogen-containing heterocyclic compound having NRF2 activation effect	CHUGAI SEIYAKU KABUSHIKI KAISHA (JP)	2025-10-14	—	—	US	disclosed
US-20250171457-A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT	CHUGAI PHARMACEUTICAL CO LTD (JP)	2025-05-29	—	—	US	disclosed
US-20250084093-A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT	CHUGAI PHARMACEUTICAL CO LTD (JP)	2025-03-13	—	—	US	disclosed
EP-4446312-A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT	CHUGAI SEIYAKU KABUSHIKI KAISHA (JP)	2024-10-16	—	—	EP	disclosed
CN-118488944-A	Nitrogen-containing heterocyclic compound having Nrf2 activation	中外制药株式会社	2024-08-13	—	—	CN	disclosed
CN-118221579-A	PRMT5 inhibitors	北京望实智慧科技有限公司	2024-06-21	—	—	CN	disclosed
WO-2023132369-A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT	中外製薬株式会社	2023-07-13	—	—	WO	disclosed
US-20140163026-A1	8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER	AFRAXIS HOLDINGS, INC. (US)	2014-06-12	—	—	US	disclosed
US-20140163026-A1	8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER	AFRAXIS HOLDINGS, INC. (US)	2014-06-12	—	—	US	disclosed
US-20140163026-A1	8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER	AFRAXIS HOLDINGS, INC. (US)	2014-06-12	—	—	US	disclosed
WO-2013043232-A2	8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER	AFRAXIS, INC. (US)	2013-03-28	—	—	WO	disclosed
US-8288552-B2	Dihydropyridone amidesas P2X7 modulators	ROCHE PALO ALTO LLC (US)	2012-10-16	—	—	US	disclosed
US-8288552-B2	Dihydropyridone amidesas P2X7 modulators	ROCHE PALO ALTO LLC (US)	2012-10-16	—	—	US	disclosed
US-8288552-B2	Dihydropyridone amidesas P2X7 modulators	ROCHE PALO ALTO LLC (US)	2012-10-16	—	—	US	disclosed
EP-2391604-A1	DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS	F. Hoffmann-La Roche AG (CH)	2011-12-07	—	—	EP	disclosed
WO-2010072605-A1	DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS	F. HOFFMANN-LA ROCHE AG (CH)	2010-07-01	—	—	WO	disclosed
WO-2010072605-A1	DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS	F. HOFFMANN-LA ROCHE AG (CH)	2010-07-01	—	—	WO	disclosed
US-20100160389-A1	DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS	ROCHE PALO ALTO LLC	2010-06-24	—	—	US	disclosed
US-20100160389-A1	DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS	ROCHE PALO ALTO LLC	2010-06-24	—	—	US	disclosed
US-20100160389-A1	DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS	ROCHE PALO ALTO LLC	2010-06-24	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-12441735-B2	Nitrogen-containing heterocyclic compound having NRF2 activation effect	KEAP1, NFE2L2, BACH1	GAA 4316/4885ABL1 2215/4885KDM4E 3660/4885
US-20100160389-A1	DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS	P2RX3, P2RX1, P2RY1	GAA 4305/4885ABL1 3113/4885KDM4E 2570/4885
US-20250171457-A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT	KEAP1, NFE2L2, BACH1	GAA 4316/4885ABL1 2215/4885KDM4E 3660/4885
US-20140163026-A1	8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER	PAK2, PAK1, PAK6	GAA 2340/4885ABL1 237/4885KDM4E 1213/4885
US-20250084093-A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT	KEAP1, NFE2L2, BACH1	GAA 4325/4885ABL1 2337/4885KDM4E 3677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.